Thymosin Alpha-1
Investigación publicada y base de evidencia
Thymosin alpha-1 (Ta1, thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha and originally isolated from thymic tissue. It acts largely through Toll-like receptor signalling on dendritic cells and monocytes, influencing T-cell differentiation, thymic output and cytokine balance. It is registered as a prescription immunomodulator in a number of countries, principally for chronic hepatitis B and as an adjuvant in sepsis and oncology, and has been studied in more than thirty controlled human trials. It is not approved by the FDA or EMA.
- Thymosin alpha-1 es un péptido de 28 aminoácidos aislado originalmente del tejido tímico.
- Ensayos humanos lo estudiaron para hepatitis B, sepsis y cáncer como adyuvante.
- El mayor ensayo en sepsis no encontró beneficio; la mayoría de evidencia viene de China e Italia.
39 estudios · 16 desde 2023 · más reciente 2026
- Estudios citados
- 39
- Publicados en 2023+
- 16
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- immunomodulation
- T-cell maturation and thymic output
- Toll-like receptor signalling
- sepsis and septic immunoparalysis
- chronic hepatitis B
- oncology adjuvant and checkpoint-inhibitor combination
- immunosenescence
- COVID-19 and viral infection
Identificadores del compuesto
- CAS
- 62304-98-7
- PubChem
- 16130571
Qué es Thymosin Alpha-1, químicamente.
- Fórmula molecular
- C129H215N33O55
- Peso molecular
- 3108.3 g/mol
- Número CAS
- 62304-98-7
- PubChem CID
- 16130571
Thymalfasin, Thymosin alpha 1, Zadaxin
Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.
39 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Revisión sistemática2026
Thymosin-ɑ1 for people with chronic hepatitis B.
Naing C, et al. · Cochrane Database Syst Rev · Cochrane systematic review and meta-analysis, 10 RCTs, n=1349 adults with chronic hepatitis B
Thymosin-alpha1 may reduce all-cause mortality (RR 0.53), serious adverse events (RR 0.72) and non-serious adverse events, with little to no effect on quality of life or histology; certainty of evidence was low for serious adverse events and very low for all other outcomes.
- 02Revisión sistemática2025
Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials
Gu B, et al. · Frontiers in Cellular and Infection Microbiology · Meta-analysis with trial sequential analysis, 11 RCTs, 1927 patients with sepsis
Pooled 28-day mortality favoured thymosin alpha-1 (OR 0.73, 95% CI 0.59 to 0.90), but the effect disappeared in high-quality (OR 0.82, 95% CI 0.65 to 1.03) and multicentre (OR 0.86, 95% CI 0.68 to 1.08) subgroups. Trial sequential analysis indicated the cumulative sample size remained inadequate.
- 03Revisión sistemática2025
Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
Tian Y, et al. · Frontiers in Immunology · Systematic review and meta-analysis of controlled trials in severe acute pancreatitis (PROSPERO CRD42024570517)
Thymosin alpha-1 was associated with fewer bloodstream (RR 0.60, 95% CI 0.38 to 0.94) and abdominal (RR 0.38, 95% CI 0.19 to 0.78) infections and a lower APACHE II score, but did not significantly shorten hospital stay or reduce lung infections.
- 04Revisión sistemática2024
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Cao A, et al. · Journal of the College of Physicians and Surgeons Pakistan · Meta-analysis of 39 randomised controlled trials, 3329 patients with acute exacerbation of COPD
Adjunctive thymosin alpha-1 was associated with higher FEV1 (MD 0.29 L), lower arterial CO2 partial pressure, shorter hospital stay (MD -5.39 days) and higher CD4+ counts and CD4+/CD8+ ratio. The authors noted that most included trials were of limited methodological quality.
- 05Revisión sistemática2023
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
Soeroto AY, et al. · Inflammopharmacology · Meta-analysis and meta-regression of 8 studies in moderate to critical COVID-19
Pooled mortality was lower with thymosin alpha-1 (RR 0.59, 95% CI 0.37 to 0.93) with high heterogeneity (I2 = 84%), but there was no difference in need for mechanical ventilation or length of stay. The authors stated that randomised trials were still required to confirm the finding.
- 06Revisión sistemática2011
Thymic peptides for treatment of cancer patients
Wolf E, et al. · Cochrane Database of Systematic Reviews · Cochrane systematic review of randomised trials of purified thymus extracts and synthetic thymic peptides in adult cancer patients
Purified thymus extracts conferred no benefit on overall survival, disease-free survival or tumour response, though they reduced severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78). For thymosin alpha-1 specifically the pooled overall survival risk ratio was 1.21 (95% CI 0.94 to 1.56), a non-significant trend; most trials carried at least moderate risk of bias.
- 07Clínico humano2026
Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance
Li ZH, et al. · Immunopharmacology and Immunotoxicology · Open-label randomised controlled trial (NCT03082885), 73 patients with HBV-related acute-on-chronic liver failure
Thymosin alpha-1 treatment increased 90-day transplant-free survival and was associated with reduced frequencies of regulatory T cells and CD226-low Treg subsets at weeks 4 to 8. The authors reported moderation of the late hyperinflammatory response without suppressing early immune activation.
- 08Clínico humano2026
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial
Xu H, et al. · BMC Medicine · Prospective phase II trial, 30 patients with cStage III gastric/gastro-oesophageal junction adenocarcinoma; serplulimab plus SOX plus thymalfasin
At a median follow-up of 14.0 months one nodal relapse and no deaths were recorded; grade 3 or higher adverse events occurred in 26.7% of patients. Flow cytometry and RNA sequencing showed CD8+ T-cell expansion and upregulation of antigen-presentation and type I interferon genes associated with thymalfasin.
- 09Clínico humano2025
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, et al. · BMJ · Multicentre double-blind placebo-controlled phase 3 RCT, 1106 adults with sepsis, 22 centres in China
28-day all-cause mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27; P=0.93), and no secondary or safety outcome differed significantly. The authors concluded there was no clear evidence that thymosin alpha-1 reduces 28-day mortality in sepsis.
- 10Clínico humano2025
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study
Yao S, et al. · Scientific Reports · Retrospective cohort, 92 patients with unresectable hepatocellular carcinoma
Adding thymosin alpha-1 was associated with longer median progression-free survival (7 versus 4 months, P=0.006) and a higher objective response rate (55.8% versus 34.7%, P=0.042). Rates of grade 1-2 and grade 3-4 adverse events did not differ between groups.
- 11Clínico humano2024
Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV
Chen C, et al. · BMC Infectious Diseases · Single-arm open-label study, 20 immunological non-responders on antiretroviral therapy, 24 weeks of subcutaneous thymosin alpha-1
CD4+ T-cell count and sjTREC rose as a trend without reaching significance at week 24, while naive CD4+ and CD8+ T-cell proportions increased significantly and PD-1 expression on CD4+ and CD8+ T cells fell. No severe adverse events occurred and HIV viral load remained stable.
- 12Clínico humano2024
A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer.
Niu W, et al. · Biotechnol Genet Eng Rev · randomised controlled trial, n=400 patients after radical resection of colorectal cancer at one hospital, XELOX chemotherapy plus thymalfasin at two dose levels (n=100 each) versus XELOX alone
Both thymalfasin groups had lower perioperative infection rates than controls (P < 0.05), with no difference between the two dose levels. The thymalfasin groups also had fewer early and late postoperative complications, lower local recurrence and distant metastasis rates, better perioperative immune indexes and longer median disease-free survival (P < 0.05).
- 13Clínico humano2023
A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report.
Tuthill CW, et al. · Int Immunopharmacol · randomised controlled pilot trial (preliminary report), n=194 patients with end-stage renal disease on haemodialysis at five dialysis centres, thymalfasin for 8 weeks versus no thymalfasin, then 4 months of follow-up
At the time of this preliminary report there had been 3 deaths in the thymalfasin group versus 7 in controls, and 12 COVID-19-related serious adverse events (5 versus 7). Antibody responses and the final safety and efficacy endpoints had not yet been analysed.
- 14Clínico humano2023
A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
Shehadeh F, et al. · J Infect Dis · prospective open-label randomised trial (NCT04487444), n=49 hospitalised patients with hypoxaemia and lymphocytopenia due to COVID-19, thymalfasin versus standard of care
Clinical recovery was more frequent with thymalfasin among patients on low-flow oxygen (subdistribution hazard ratio 1.48) and high-flow oxygen (1.28), but neither difference was significant. CD4+ T-cell counts rose faster with thymalfasin in low-flow patients (P = .01), and nine serious adverse events in treated patients were judged unrelated to the drug.
- 15Clínico humano2022
Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial
Ke L, et al. · Intensive Care Medicine · Multicentre double-blind placebo-controlled RCT, 508 patients with predicted severe acute necrotising pancreatitis
Infected pancreatic necrosis occurred in 15.7% of the thymosin alpha-1 group versus 18.1% of placebo (difference -2.4%, 95% CI -7.4 to 5.1; P=0.48), with no difference across four predefined subgroups. New-onset organ failure, bleeding and gastrointestinal fistula rates were also similar.
- 16Clínico humano2022
A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.
Shetty A, et al. · Indian J Crit Care Med · double-blind multicenter randomized placebo-controlled phase III trial, n=105 moderate-to-severe COVID-19 patients, 28-day follow-up
Death rate was 11.1% with thymosin alpha 1 versus 38.5% with placebo; 67 adverse events occurred in 42 patients, mostly mild, with 8 serious events (deaths).
- 17Clínico humano2022
Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.
Chen JF, et al. · Hepatol Int · open-label randomised controlled trial (NCT03082885), 120 patients with HBV-related acute-on-chronic liver failure enrolled (56 thymosin alpha-1, 58 standard medical therapy), 12 weeks of treatment
90-day liver transplantation-free survival was 75.0% with thymosin alpha-1 versus 53.4% with standard therapy (p = 0.030), although competing-risk analysis showed no significant survival difference. New infections (32.1% vs 58.6%) and hepatic encephalopathy (8.9% vs 24.1%) were less frequent with thymosin alpha-1.
- 18Clínico humano2022
Value of Thymosin α1 Combined With Blood Purification to Increase Successful Rescues of Shock Patients.
Bai L, et al. · Altern Ther Health Med · randomised controlled trial, n=86 patients with septic shock in an emergency department, thymosin alpha-1 plus blood purification (43) versus blood purification alone (43), one-year follow-up
Rescue success rate and adverse events did not differ between groups (P > .05), while shock duration and ICU stay were shorter and the overall response rate higher with thymosin alpha-1 (P < .05). Overall survival at one-year follow-up did not differ significantly.
- 19Clínico humano2021
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
Liu J, et al. · Front Immunol · multicentre retrospective cohort in five tertiary hospitals in Hubei, 306 COVID-19 patients treated with thymosin alpha-1 and 1,976 not treated
Crude non-recovery, in-hospital mortality, intubation, ARDS and acute kidney injury rates were all higher in the thymosin alpha-1 group, and after adjustment thymosin alpha-1 use remained associated with a higher non-recovery rate (OR 1.5, 95% CI 1.1-2.1, p = 0.028). The association was stronger in more severe patients and with later initiation.
Hallazgo de seguridad reportado. In this observational cohort, thymosin alpha-1 use was associated with a higher adjusted non-recovery rate in COVID-19 (OR 1.5), especially in more severe disease.
- 20Clínico humano2018
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
Wu X, et al. · Expert Opinion on Biological Therapy · Prospective multicentre randomised open-label study, 690 patients with HBV-related compensated cirrhosis, 52 weeks of treatment
Cumulative incidence of liver decompensation, hepatocellular carcinoma or death was similar between entecavir plus thymosin alpha-1 and entecavir alone, as were virologic, serologic and biochemical responses at week 104. Both regimens were well tolerated and the combination showed only a non-significant tendency to reduce hepatocellular carcinoma.
- 21Clínico humano2015
Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z, et al. · Immunopharmacol Immunotoxicol · randomised placebo-controlled trial, eighty-four patients with acute exacerbation of COPD on routine treatment, subcutaneous thymosin alpha-1 or placebo, assessed after four weeks
Compared with placebo, the thymosin alpha-1 group had greater improvements in PaO2, PaCO2 and pulmonary function (p < 0.01) and in CD4+ T-cell count, CD4+/CD8+ ratio and IFN-gamma/IL-4 ratio, with larger falls in IL-4, IL-8 and leukotriene B4 (p < 0.05 or 0.01).
- 22Clínico humano2013
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Wu J, et al. · Critical Care · Multicentre single-blind RCT, 361 patients with severe sepsis, six teaching hospitals in China
28-day all-cause mortality was 26.0% with thymosin alpha-1 versus 35.0% in controls, a marginal difference (relative risk 0.74, 95% CI 0.54 to 1.02). Monocyte HLA-DR expression improved more in the treated group at days 3 and 7, and no serious drug-related adverse events were recorded.
- 23Clínico humano2012
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
Ciancio A, et al. · J Viral Hepat · randomised placebo-controlled multicentre trial, n=552 patients with chronic hepatitis C not responding to prior peginterferon plus ribavirin, thymosin alpha-1 or placebo added to peginterferon alfa-2a plus ribavirin for 48 weeks
Sustained viral response in the intention-to-treat population was similar with thymosin alpha-1 and placebo (12.7% vs 10.5%; P = 0.407), and the incidence of adverse events did not differ. Among patients who completed all 48 weeks, sustained response was higher with thymosin alpha-1 (41.0% vs 26.3%; P = 0.048).
- 24Clínico humano2012
Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.
Carraro G, et al. · Vaccine · controlled pilot trial in haemodialysis patients given an adjuvanted pandemic H1N1v influenza vaccine alone or with thymosin alpha-1 (Zadaxin) at two doses; 94 in the intention-to-treat and 99 in the safety population, followed to day 168
At day 21 both vaccine-plus-thymosin alpha-1 groups had better haemagglutination-inhibition geometric mean titres and ratios than vaccine alone and fully met the CHMP criteria, although titres fell more by day 42 in the thymosin alpha-1 groups. No adverse event was judged related to thymosin alpha-1, which did not affect haematology or blood chemistry.
- 25Clínico humano2010
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma
Maio M, et al. · Journal of Clinical Oncology · Randomised five-arm trial, 488 patients with metastatic melanoma
Median overall survival was 9.4 months with thymosin alpha-1 versus 6.6 months in the control arm (hazard ratio 0.80, 95% CI 0.63 to 1.02; P=0.08), with a similar non-significant trend for progression-free survival. Adding thymosin alpha-1 did not increase toxicity.
- 26Clínico humano2008
Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study.
Lee HW, et al. · J Gastroenterol Hepatol · prospective randomised comparative multicentre pilot study, sixty-seven treatment-naive patients with HBeAg-positive chronic hepatitis B, thymosin alpha-1 plus lamivudine for 24 weeks followed by lamivudine, versus lamivudine alone
HBeAg seroconversion at 24 weeks was 26.5% with the combination versus 6.1% with lamivudine alone (P = 0.024), but the difference at 52 weeks (26.5% vs 12.1%) was not significant (P = 0.138). Viral rebound during treatment by 52 weeks occurred in 35.3% versus 21.2% (P = 0.201).
- 27Clínico humano2007· Chinese (English abstract)
[Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].
Cooperative Group of immunomodulatory Therapy of Sepsis, Lin HY · Zhonghua Yi Xue Za Zhi · multicentre prospective randomised controlled trial in 26 university teaching hospitals, n=433 adults with severe sepsis; ulinastatin plus thymosin alpha-1 (Maipuxin) added to standard care for 7 days versus standard care alone, run as two sequential trials at a lower and a higher dose
In the first trial (91 cases) the lower-dose combination did not differ from control at 28 days. In the second trial (342 cases) 28-day mortality was 25.14% with the higher-dose combination versus 38.32% with control (P=0.0088) and 90-day mortality 37.14% versus 52.10% (P=0.0054); thymosin alpha-1 was always given together with ulinastatin, so its separate effect was not tested.
- 28Clínico humano2006
A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
Lim SG, et al. · Antivir Ther · double-blind randomised placebo-controlled multicentre trial, n=98 patients with HBeAg-positive chronic hepatitis B, thymosin alpha-1 or placebo added to lymphoblastoid interferon for 24 weeks, primary endpoint at 72 weeks
HBeAg loss at 72 weeks was 45.8% with combination therapy versus 28.0% with interferon alone (difference 17.8%, 95% CI -1.2% to 35.3%, P = 0.067). HBeAg seroconversion, histology, ALT normalisation and HBV DNA loss did not differ significantly.
- 29Clínico humano2005
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.
Iino S, et al. · J Viral Hepat · randomised multicentre dose-comparison trial without an untreated control, n=316 Japanese patients with chronic hepatitis B, thymosin alpha-1 monotherapy at two doses for 24 weeks, 72-week observation
At week 72, 36.4% of the higher-dose group had normalised ALT, 30% had cleared HBV-DNA by branched DNA assay (15% by transcription-mediated amplification) and 22.8% had cleared HBe-antigen, with similar rates in the lower-dose group. Adverse drug reactions were mild, mostly fluctuations in liver enzymes, and occurred at similar rates with both doses.
- 30Clínico humano1999
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
Mutchnick MG, et al. · J Viral Hepat · phase III multicentre randomised double-blind placebo-controlled trial, n=97 patients with HBeAg- and HBV DNA-positive chronic hepatitis B, 6 months of treatment and 6 months of follow-up
A complete response at 12 months occurred in 7 (14%) thymosin alpha-1 patients versus 2 (4%) placebo patients (P = 0.084), and sustained loss of HBV DNA with negative HBeAg in 12 (25%) versus 6 (13%) (P < 0.11). The authors stated that the results did not confirm the efficacy reported in earlier studies.
- 31Clínico humano1999
Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.
Rost KL, et al. · Int J Clin Pharmacol Ther · randomised three-way crossover pharmacokinetic study in nine healthy volunteers, single and 5-day subcutaneous administration of three thymosin alpha-1 formulations (Zadaxin, Timosina, Tal-HLR)
Thymosin alpha-1 was well absorbed with a mean tmax of 1-2 hours, had an elimination half-life under 3 hours with no accumulation over 5 days, and distributed within the extracellular volume. Exposure (AUC and Cmax) was similar for Zadaxin and the Roche formulation but higher with Timosina.
- 32Clínico humano1998
Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
Sherman KE, et al. · Hepatology · randomised double-blind placebo-controlled three-arm trial, one hundred nine patients with biopsy-confirmed chronic hepatitis C: thymosin alpha-1 plus interferon, interferon plus placebo, or placebo for both, 26 weeks
End-of-treatment biochemical response was 37.1% with the combination, 16.2% with interferon alone and 2.7% with placebo (combination vs interferon P = .04), and HCV RNA clearance was 37.1% versus 18.9%. Cumulative sustained biochemical responses were 14.2% and 8.1% in the combination and interferon arms.
- 33Clínico humano1998
Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.
Chien RN, et al. · Hepatology · randomised controlled trial, n=98 patients with chronic hepatitis B in three arms: 26 weeks of thymosin alpha-1, 52 weeks of thymosin alpha-1, or no treatment, assessed at 18 months
At 18 months complete virological response (clearance of HBV DNA and HBeAg) was 40.6% with 26 weeks of treatment and 26.5% with 52 weeks versus 9.4% in untreated controls (P=.004 and P=.068). Response rates were similar at the end of therapy and accumulated afterwards; no responder lost HBsAg and no significant side effects were observed.
- 34Clínico humano1996
A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.
Andreone P, et al. · Liver · randomised double-blind placebo-controlled pilot trial, nineteen Italian patients with biopsy-proven chronic active hepatitis C, six months of thymosin alpha-1 or placebo and six months of follow-up
One thymosin alpha-1 patient normalised ALT by the end of treatment but relapsed during follow-up; mean ALT did not change significantly in either group and no patient cleared HCV-RNA. Apart from local discomfort at injection sites no side effects were reported, and the authors concluded the regimen was not effective.
- 35Clínico humano1989
Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study.
Gravenstein S, et al. · J Am Geriatr Soc · randomized double-blind placebo-controlled trial, n=90 men aged 65-99 receiving trivalent influenza vaccine (85 analysed)
Thymosin alpha 1 or placebo was given alongside influenza vaccination; groups were comparable and no toxicity was observed in either group. Antibody-response results are beyond the truncated PubMed abstract.
- 36Clínico humano1985
A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.
Schulof RS, et al. · J Biol Response Mod · randomised placebo-controlled trial, n=42 patients with non-small cell lung cancer after radiotherapy, two synthetic thymosin alpha-1 regimens versus placebo, 15 weeks of immune monitoring
Placebo-treated patients showed no recovery of T-cell number or function, whereas one thymosin regimen normalised T-cell function (p = 0.04) and the other maintained normal helper T-cell percentages (p = 0.04). Thymosin treatment was associated with improved relapse-free and overall survival, most clearly in patients with non-bulky tumours.
- 37Animal in vivo2026
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Wei Y, et al. · Cancer Research · Tumour-bearing mice plus patient plasma samples; dendritic cell mechanistic work
Circulating thymosin alpha-1 fell after chemotherapy in both patients and tumour-bearing mice; the peptide protected apoptotic-body-derived miR146a-5p from lysosomal degradation, enabling TLR7-dependent dendritic cell maturation. Supplementation synergised with chemotherapy to control established tumours in a TLR7-dependent manner.
- 38Revisión2025
Aging and Thymosin Alpha-1
Simonova MA, et al. · International Journal of Molecular Sciences · Narrative review of thymic involution and immunosenescence
The review summarised preclinical and clinical evidence that thymosin alpha-1 stimulates T-cell differentiation and thymic output and can improve vaccine responses in older adults. The authors noted that long-term efficacy and safety in geriatric populations remain unvalidated.
- 39Reporte de caso2026
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
Li T, et al. · Clin Case Rep · single case, patient with nasopharyngeal carcinoma treated with sintilimab (a PD-1 inhibitor) plus thymosin alpha-1
The patient developed multisystem immune-related adverse events with high fever, rash, interstitial pulmonary oedema and multiple organ failure after combined checkpoint-inhibitor and thymosin alpha-1 treatment. The authors discussed the risk of immune overactivation with this combination.
Hallazgo de seguridad reportado. Multisystem immune-related adverse events with multiple organ failure followed sintilimab combined with thymosin alpha-1.
Lo que esta evidencia no establece.
The largest and most rigorous trial to date, the phase 3 TESTS study, found no mortality benefit in sepsis, and the pooled meta-analytic signal disappears when analysis is restricted to high-quality multicentre trials; the same pattern of positive small trials and null large trials recurs in pancreatitis and hepatitis B cirrhosis. The great majority of randomised evidence originates from China and Italy, thymosin alpha-1 is not approved by the FDA or EMA, and there are no controlled human trials testing it as a longevity or healthy-ageing intervention.
Preguntas comunes sobre la investigación.
- What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid acetylated peptide first isolated from thymosin fraction 5, a thymic tissue extract. Its synthetic form carries the international non-proprietary name thymalfasin. It is supplied here as a lyophilised research material.
- Is Thymosin Alpha-1 an approved medicine?
As neutral regulatory background: review articles record that thymalfasin is approved in more than 35 countries, under the trade name Zadaxin in several of them, for hepatitis B and hepatitis C. That approval applies to licensed pharmaceutical product in those jurisdictions. It does not apply to this research material, which is not an approved medicine and is not supplied for human use.
- How does it differ from TB-500 and Thymosin Beta-4?
Despite the shared name, the alpha and beta thymosins are unrelated molecules from the same original tissue fractionation. Thymosin Alpha-1 is a 28-amino-acid peptide studied for immune signalling; Thymosin Beta-4 — and its fragment TB-500 — is a 43-amino-acid actin-sequestering peptide studied in tissue-repair models.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.